Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC
- Status
- UNKNOWN
- Phase
- PHASE3
Nordic 8 - A Phase II Trial
- Status
- COMPLETED
- Phase
- PHASE2
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE3
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
- Status
- COMPLETED
- Phase
- PHASE2
Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
- Status
- COMPLETED
- Phase
- NA
Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- UNKNOWN
- Phase
- PHASE2
Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms
- Status
- COMPLETED
- Phase
- N/A
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases
- Status
- UNKNOWN
- Phase
- PHASE2
Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer
- Status
- TERMINATED
- Phase
- NA
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2